Bristol Myers Squibb Stock Today
| BMY Stock | USD 59.27 0.53 0.90% |
Performance12 of 100
| Odds Of DistressLess than 15
|
Bristol Myers is trading at 59.27 as of the 28th of November 2024; that is 0.90% up since the beginning of the trading day. The stock's open price was 58.74. Bristol Myers has less than a 15 % chance of experiencing some financial distress in the next two years of operation and had a good performance during the last 90 days. Note, on September 2, 2024, Representative John James of US Congress acquired under $15k worth of Bristol Myers Squibb's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 1st of January 1972 | Category Healthcare | Classification Health Care |
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company was founded in 1887 and is headquartered in New York, New York. Bristol-Myers Squibb operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. The company has 2.03 B outstanding shares of which 23.42 M shares are currently shorted by investors with about 2.3 days to cover. More on Bristol Myers Squibb
Moving against Bristol Stock
Bristol Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Chairman | Giovanni Caforio | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Compulsion (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NYSE Composite, NYSE 100 Index, SP 500 Index, ARCA Pharmaceutical, SP 100, Compulsion, Health Care, Pharmaceuticals, Drug Manufacturers—General, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Excise Tax Activities | Animal TestingCatholic | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsBristol Myers can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Bristol Myers' financial leverage. It provides some insight into what part of Bristol Myers' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bristol Myers Squibb (BMY) is traded on New York Stock Exchange in USA. It is located in Route 206 & Province Line Road, Princeton, NJ, United States, 08543 and employs 34,100 people. Bristol Myers is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Mega-Cap' category with a total capitalization of 119.14 B. Bristol Myers Squibb runs under Pharmaceuticals sector within Health Care industry. The entity has 2.03 B outstanding shares of which 23.42 M shares are currently shorted by investors with about 2.3 days to cover.
Bristol Myers Squibb has about 9.12 B in cash with 13.86 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.21.
Check Bristol Myers Probability Of Bankruptcy
Ownership AllocationBristol Myers holds a total of 2.03 Billion outstanding shares. The majority of Bristol Myers Squibb outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Bristol Myers Squibb to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Bristol Myers. Please pay attention to any change in the institutional holdings of Bristol Myers Squibb as this could imply that something significant has changed or is about to change at the company. Please note that on September 2, 2024, Representative John James of US Congress acquired under $15k worth of Bristol Myers Squibb's common stock.
Check Bristol Ownership Details
Bristol Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Northern Trust Corp | 2024-09-30 | 21.2 M | |
| Legal & General Group Plc | 2024-06-30 | 20.2 M | |
| Ubs Asset Mgmt Americas Inc | 2024-09-30 | 19.1 M | |
| Bank Of America Corp | 2024-06-30 | 18.2 M | |
| Ameriprise Financial Inc | 2024-06-30 | 17.7 M | |
| Bank Of New York Mellon Corp | 2024-06-30 | 16.2 M | |
| Goldman Sachs Group Inc | 2024-06-30 | 15.7 M | |
| Dodge & Cox | 2024-09-30 | 15.6 M | |
| T. Rowe Price Associates, Inc. | 2024-06-30 | 15.3 M | |
| Vanguard Group Inc | 2024-09-30 | 188.6 M | |
| Blackrock Inc | 2024-06-30 | 158.7 M |
Bristol Myers Historical Income Statement
Bristol Stock Against Markets
Bristol Myers Corporate Directors
| Karen Vousden | Independent Director | Profile | |
| Michael Bonney | Independent Director | Profile | |
| Robert Bertolini | Independent Director | Profile | |
| Gerald Storch | Independent Director | Profile |
Additional Tools for Bristol Stock Analysis
When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.